by | Jun 3, 2024 | Publications
Rinsho Ketsueki. 2024;65(5):428-438. doi: 10.11406/rinketsu.65.428. ABSTRACT Over the past decade, new therapeutic modalities have markedly improved clinical outcomes for patients with multiple myeloma. Recently, immunotherapy using both bispecific antibodies (BsAb)...
by | Jun 3, 2024 | Publications
Clin Chim Acta. 2024 May 31:119756. doi: 10.1016/j.cca.2024.119756. Online ahead of print. ABSTRACT BACKGROUND: Iron studies are critical for diagnosing iron deficiency and hemochromatosis. We present a case exhibiting macrocytic anemia with perplexingly high plasma...
by | Jun 2, 2024 | Publications
Int J Lab Hematol. 2024 May 31. doi: 10.1111/ijlh.14324. Online ahead of print. ABSTRACT INTRODUCTION: The global burden of multiple myeloma (MM) is increasing every year. Here, we have developed machine learning models to provide a reference for the early detection...
by | Jun 1, 2024 | Publications
Lancet Oncol. 2024 May 28:S1470-2045(24)00094-9. doi: 10.1016/S1470-2045(24)00094-9. Online ahead of print. ABSTRACT Chimeric antigen receptor (CAR) T-cell therapy has shown promise in patients with late-line refractory multiple myeloma, with response rates ranging...
by | Jun 1, 2024 | Publications
Clin Lymphoma Myeloma Leuk. 2024 May 4:S2152-2650(24)00176-9. doi: 10.1016/j.clml.2024.05.006. Online ahead of print. ABSTRACT BACKGROUND: Anti-BCMA-directed chimeric antigen receptor (CAR) T cells are effective treatment for patients with refractory/relapsed multiple...
by | Jun 1, 2024 | Publications
Blood Cancer J. 2024 May 31;14(1):90. doi: 10.1038/s41408-024-01068-w. ABSTRACT The presence of extramedullary disease (EMD) has been associated with poor outcomes in patients with relapsed-refractory multiple myeloma (RRMM). Herein, we report the outcomes of RRMM...
